Month: August 2025

ABN AMRO announces EUR 250 million share buyback programme ABN AMRO today announced the start of a share buyback programme under which it plans to repurchase depositary receipts and ordinary shares of ABN AMRO Bank N.V. for a maximum total value of EUR 250 million and for a number of shares not exceeding the authority granted by the general meeting of shareholders on 23 April 2025 (10% of the issued shares). The share buyback programme will commence on 7 August 2025 and is expected to end no later than December 2025. The purpose of the programme is to reduce ABN AMRO’s share capital. ABN AMRO’s CET1 ratio at the end of the second quarter of 2025 was 14.8%. The capital required for the announced share buyback programme has been reserved and is already excluded from the 2025 Q2 capital ratios. The repurchased shares will be cancelled in...

Perth, Aug. 06, 2025 (GLOBE NEWSWIRE) — FY25 RESULTS INVESTOR WEBINAR / CALL Perth, Western Australia/August 6, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its FY25 Results, which are anticipated for release around 8:30am AEST on Thursday August 28, 2025. CALL DETAILSAustralia: Thursday August 28, 2025 Perth – 7:00am Sydney/Melbourne – 9:00am Canada: Wednesday August 27, 2025 Vancouver – 4:00pm Toronto – 7:00pm UK: Thursday August 27, 2025 London – 12:00amRegister for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_i2PsK9i-SC-DnuJqKimr4A After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the following numbers and enter...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that it has arranged a non-brokered private placement (the “Offering”) of up to a combined aggregate of 60,000,000 flow-through (“FT Units”) and non-flow through (“NFT Units”) units at a price of $0.20 per NFT Unit and FT Unit for aggregate gross proceeds of up to $12,000,000. The Offering is expected to close in multiple tranches, the first of which is anticipated to close on or before August 15, 2025. The Company anticipates that, upon completion of the Offering, a new Control Person (as defined below), Mr. Matthew Mason (“Mr. Mason”), will be created though Mr. Mason’s...

GUADALAJARA, Mexico, Aug. 05, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for July 2025, compared with July 2024. During this period, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 1.8%, compared to July 2024. Guadalajara and Puerto Vallarta airports presented an increase in passenger traffic of 0.7% and 0.4%, respectively, while Los Cabos remained flat and Tijuana airport decreased 3.1%, compared to July 2024. On the other hand, Montego Bay presented an increase in passenger traffic of 15.2%, compared to July 2024. Domestic Terminal Passengers (in thousands):Airport Jul-24 Jul-25 % Change Jan – Jul 24 Jan – Jul 25 % ChangeGuadalajara 1,085.2 1,092.5 0.7% 6,751.7 7,204.6 6.7%Tijuana* 763.8 776.3 1.6% 4,847.2 4,972.9 2.6%Los...

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight lossTokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline...

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Galantas Gold Corporation (TSX-V & AIM: GAL; OTCQB: GALKF) (“Galantas” or the “Company”) is pleased to report the results of its Annual and Special Meeting held on August 5, 2025. All resolutions were passed by shareholders. Shareholders voted in favour of the election of all director nominees for the ensuing year: Mario Stifano, James B. Clancy, Róisín Magee, David Cather, and Brent Omland. Shareholders also voted in favour of (i) appointing Clearhouse LLP, Chartered Professional Accountants as the auditors of the Company for the ensuing year and authorizing the Board of Directors to fix their remuneration; (ii) ratifying and confirming the “rolling” stock option plan of the Company as more particularly set out in its Management Information Circular; and in accordance with the announcement...

Ongoing momentum in FAST channel sales drives revenue growth and profitabilityOrganic growth of 12.5% year-over-year in Broadcast and Recurring Commercial Music Revenues; Revenues increased 7.4% to $95.6 million in the first quarter of 2026 from $89.1 million in the first quarter of 2025; Adjusted EBITDA(1) rose 8.3% to $33.7 million in the first quarter of 2026 from $31.1 million in the same period in 2025. Adjusted EBITDA(1) by segment was $24.4 million or 39.8% of revenues for Broadcasting and Commercial Music, $11.0 million or 32.3% of revenues for Radio, and $(1.8) million for Corporate; Net income increased to $16.8 million, or $0.24 per share, in the first quarter of 2026 compared to $7.3 million, or $0.11 per share, in the first quarter of 2025; Adjusted Net income(1) grew 53.0% to $21.3 million, or $0.31 per share, in the first...